Erschienen in:
04.12.2019 | ASO Author Reflections
ASO Author Reflections: What Is the Best Treatment for Gastric Cancer with Positive Peritoneal Lavage Cytology or Localized Peritoneum Metastasis?
verfasst von:
Toshifumi Yamaguchi, MD, PhD, Atsuo Takashima, MD, PhD, Narikazu Boku, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Intraoperative peritoneal lavage cytology (CY1) and local peritoneal metastasis (P1a) are important risk factors for peritoneal recurrence and prognostic factors for overall survival (OS) in gastric cancer (GC).
1 Although standard treatment for GC with CY1 and/or P1a has not been established, gastrectomy with lymph node dissection leaving no macroscopically visible disease followed by S-1 monotherapy is the most widely accepted therapeutic strategy.
2 However, the prognosis of GC patients with CY1 remains poor. The cisplatin plus S-1(CS) regimen has also been used for GC patients with CY1 and/or P1a as postoperative chemotherapy after gastrectomy, considering that these patients are stage IV.
3 However, there are no published comparisons of S-1 and CS in this multimodality treatment strategy. The aim of this study
4 is to compare whether the S-1 or CS regimen provides a survival benefit when given as postoperative chemotherapy after surgery that left no macroscopically visible disease in GC patients with CY1 and/or P1a. …
